Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02978235
Other study ID # TAS-4464-101
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date March 1, 2017
Est. completion date February 1, 2018

Study information

Verified date June 2021
Source Taiho Oncology, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.


Description:

The trial was put on Clinical Hold prior to Phase 2 due to cases of drug induced liver injury meeting the criteria for Hy's Law. Background and Rationale: • TAS4464 is an investigational NEDD8 activating enzyme (NAE) inhibitor, a compound which may affect cancer cell growth and survival. Thus, TAS4464 may help in the treatment of cancer. Phase 1: Primary: - To investigate the safety and tolerability of TAS4464 - To identify a tolerated dose of TAS4464 Secondary: - To investigate the preliminary efficacy of TAS4464 - To investigate the pharmacokinetics (PK) and the pharmacogenomics (PGx) of TAS4464 - To investigate the pharmacodynamics of TAS4464


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date February 1, 2018
Est. primary completion date February 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provide written informed consent 2. Women of child-bearing potential must have a negative pregnancy test Multiple Myeloma: Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with at least two prior lines of therapy. Lymphoma: Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received. Exclusion Criteria: 1. Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464: 1. Major surgery within 28 days 2. Radiation/chemotherapy within 21 days 3. Monoclonal antibodies within 28 days 4. Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days 5. Proteasome inhibitors within 14 days 6. Immunomodulatory agents within 7 days 7. Stem cell transplant within 3 months 8. Current immunosuppressive treatment for graft versus host disease 9. Current use of an investigational agent 2. Active graft versus host disease 3. Known serious illness or medical condition 4. Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class 5. Pregnant or breast-feeding female

Study Design


Intervention

Drug:
TAS4464
Intravenous (IV) Infusion

Locations

Country Name City State
United States Center for Cancer and Blood Disorders Bethesda Maryland
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Gabrail Cancer Center Canton Ohio
United States Weisberg Cancer Treatment Center Farmington Hills Michigan
United States John Theurer Cancer Center at Hackensack Meridian Health Hackensack New Jersey
United States Icahn School of Medicine at Mount Sinai New York New York
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Taiho Oncology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients experiencing any dose-limiting toxicities, during dose escalation period, to determine maximum tolerated dose of TAS4464, using NCI CTCAE criteria, laboratory testing, performance status assessments, and other routine visit procedures Completion of Cycle 1 (28 days)
Primary Efficacy of TAS4464, defined as Objective Response Rate (ORR) per IWG criteria (NHL) and IMWG criteria (MM). This will take into consideration routine assessments including: imaging scans, physical exams, blood tests, urine tests and biopsy results Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1